· Trials · Trials Desk
VK3019 expands Viking beyond its lead GLP-1/GIP dual agonist VK2735 into the amylin class Novo Nordisk is pursuing with CagriSema. Shares climbed 22% on the news as the pipeline diversifies ahead of expected Phase 3 catalysts.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.